Mylan sued by maker of anti-seizure drug
Generic drugmaker Mylan Inc. was sued by the makers of Banzel after it was the first to ask the Food and Drug Administration to approve a generic version of the anti-seizure drug, the Cecil-based company said Friday.
Separately, Mylan said that it expects to begin selling a generic version of multiple sclerosis drug Copaxone next year after a federal appeals court reversed a lower court ruling that had gone against the company.
Last year, U.S. District Court for the Southern District of New York ruled that Mylan had infringed on a Copaxone patent held Teva Pharmaceuticals.
“We are very pleased with today's ruling. and we expect that it will allow Mylan to launch its generic version of Copaxone on May 25, 2014,” CEO Heather Bresch said.
In the lawsuit over Banzel, Mylan said Japanese drugmaker Eisai and Switzerland's Novartis Pharma AG filed a suit in federal court in Delaware this week alleging Mylan's copy of Banzel infringes on patents held by Eisai and Novartis.
Banzel had U.S. sales of $78.4 million in the 12 months ended March 31.
Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or firstname.lastname@example.org.
Add Alex Nixon to your Google+ circles.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Rossi: Liriano no ace, but he’s Bucs’ key
- Derry Township assault suspect arrested
- Squirrel Hill street that had been paved getting another pave job
- Clemson’s Stoudt is one of the unheralded ACC QBs trying to break out
- Moody’s downgrades Pa. rating; Corbett ponders pension reform session
- Pirates notebook: Polanco, Puig held out of series opener
- Latrobe’s Ci Medical Technologies transforms to medical device business
- Dodgers rough up rusty starter Volquez, knock off Pirates at PNC Park
- ACC notebook: Pitt predicted to finish 6th in Coastal Division
- TSA fee increase this week arrives with load of complaints
- Sewickley lawyer sues pharmacies, alleges ID theft with pills